This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Arch Dermatol. 1988;124(1):21-22.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

An omission from the list of interferon-responsive diseases of interest to the dermatologist cited in Edwards' editorial¹ is acquired immunodeficiency syndrome-associated Kaposi's sarcoma. This tumor, occurring primarily in young homosexual men with human immunodeficiency virus infection, was first shown to be responsive to high doses of recombinant interferon alfa by Krown et al,² who observed complete or partial (>50% ) tumor regression in five of 12 patients treated with daily intramuscular doses of 36- or 54-million units. Subsequent studies have confirmed the therapeutic activity of high doses (>20 million units per square meter) of recombinant^3,4 and lymphoblastoid^5,6 interferon alfa preparations. Estimates of the true response rate for high-dose interferon have been of the order of 25% to 30%, but have indicated minimal activity for lower, better tolerated dosage regimens.^3-5 Patients whose tumors responded to interferon therapy had a significantly longer survival period and . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?